drugset / Trial / NCT00589394

Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine

NCT00589394

Phase 1 Completed 100 enrolled Mayo Clinic
NaSingle-groupOpen-labelDiagnostic

Summary

The lack of clear guidelines and studies addressing the proper response to the pneumococcal vaccine (Pneumovax ®) has hampered our ability to diagnosis and care for our immunodeficiency patients. Should an age matched normal response range to the Pneumovax ® be established, it would have a profound impact in the diagnosis, safety and care of immunodeficiency patients. Moreover, characterizing the B cell compartments response to the Pneumovax ® may better delineate the mechanism of protective immunity from Pneumovax ® and provide an additional tool for the diagnosis and care for immunodeficiency patients.

Timeline

Start
2007-07
Primary completion
2008-12
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pneumovax 23 Vaccine

Indications

No indication recorded.